[1] Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006; 83: 1467S-1476S.
[2] Mozaffarian D, Wu JHY. Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events. Journal of the American College of Cardiology 2011; 58: 2047–2067.
[3] Simopoulos AP. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases: Experimental Biology and Medicine. Epub ahead of print 1 June 2008. DOI: 10.3181/0711-MR-311.
[4] Janssen CIF, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Progress in Lipid Research 2014; 53: 1–17.
[5] Harris WS, Mozaffarian D, Lefevre M, et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 2009; 139: 804S–19S.
[6] Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Alternative Medicine review 2007; 12: 207–227.
[7] Zadeh-Ardabili PM, Rad SK, Rad SK, et al. Antidepressant–like effects of fish, krill oils and Vit B12 against exposure to stress environment in mice models: current status and pilot study. Scientific Reports 2019; 9: 19953.
[8] Bosma-den Boer MM, van Wetten M-L, Pruimboom L. Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recovering. Nutr Metab (Lond) 2012; 9: 32.
[9] Bradbury J. Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients 2011; 3: 529–554.
[10] Bradbury J, Brooks L, Myers SP. Are the Adaptogenic Effects of Omega 3 Fatty Acids Mediated via Inhibition of Proinflammatory Cytokines? Evidence-Based Complementary and Alternative Medicine 2011; 2012: e209197.
[11] McDaniel JC, Massey K, Nicolaou A. Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds: Fish oil supplementation. Wound Repair and Regeneration 2011; 19: 189–200.
[12] Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015; 1851: 469–484.
[13] Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med 2017; 58: 1–11.
[14] Chilton-Lopez null, Surette ME, Swan DD, et al. Metabolism of gammalinolenic acid in human neutrophils. J Immunol 1996; 156: 2941–2947.
[15] Chapkin RS, Miller CC, Somers SD, et al. Ability of 15-hydroxyeicosatrienoic acid (15-OH-20:3) to modulate macrophage arachidonic acid metabolism. Biochemical and Biophysical Research Communications 1988; 153: 799–804.
[16] Kapoor R, Huang Y-S. Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid. CPB 2006; 7: 531–534.
[17] Layé S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 295–303.
[18] Dobryniewski J, Szajda SD, Waszkiewicz N, et al. [Biology of essential fatty acids (EFA)]. Przegl Lek 2007; 64: 91–99.
[19] De Smedt-Peyrusse V, Sargueil F, Moranis A, et al. Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. J Neurochem 2008; 105: 296–307.
[20] Giordano E, Visioli F. Long-chain omega 3 fatty acids: Molecular bases of potential antioxidant actions. Prostaglandins, Leukotrienes and Essential Fatty Acids 2014; 90: 1–4.
[21] Barros MP, Poppe SC, Bondan EF. Neuroprotective Properties of the Marine Carotenoid Astaxanthin and Omega-3 Fatty Acids, and Perspectives for the Natural Combination of Both in Krill Oil. Nutrients 2014; 6: 1293–1317.
[22] Yamagata K. Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease. Lipids in Health and Disease 2017; 16: 118.
[23] Hidayat K, Yang J, Zhang Z, et al. Effect of omega-3 long-chain polyunsaturated fatty acid supplementation on heart rate: a meta-analysis of randomized controlled trials. European Journal of Clinical Nutrition 2018; 72: 805–817.
[24] Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of Hypertension 2002; 20: 1493–1499.
[25] Harris WS. n-3 fatty acids and serum lipoproteins: human studies. The American Journal of Clinical Nutrition 1997; 65: 1645S-1654S.
[26] Cunnane S, Stewart K. Human Brain Evolution: The Influence of Freshwater and Marine Food Resources. John Wiley & Sons, 2010.
[27] Galli C, Marangoni F. N-3 fatty acids in the Mediterranean diet. Prostaglandins, Leukotrienes and Essential Fatty Acids 2006; 75: 129–133.
[28] Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91: 439–446.
[29] DiNicolantonio JJ, O’Keefe JH. Importance of maintaining a low omega–6/omega–3 ratio for reducing inflammation. Open Heart 2018; 5: e000946.
[30] Gregory MK, Gibson RA, Cook-Johnson RJ, et al. Elongase reactions as control points in long-chain polyunsaturated fatty acid synthesis. PLoS One 2011; 6: e29662.
[31] Fares H, Lavie CJ, DiNicolantonio JJ, et al. Omega-3 Fatty Acids: A Growing Ocean of Choices. Curr Atheroscler Rep 2014; 16: 389.
[32] Ulven T, Christiansen E. Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu Rev Nutr 2015; 35: 239–263.
[33] Li L, Wang C, Jiang S, et al. The absorption kinetics of Antarctic krill oil phospholipid liposome in blood and the digestive tract of healthy mice by single gavage. Food Science and Human Wellness 2020; 9: 88–94.
[34] Ahn SH, Lim SJ, Ryu YM, et al. Absorption rate of krill oil and fish oil in blood and brain of rats. Lipids Health Dis 2018; 17: 162.
[35] Sugasini D, Thomas R, Yalagala PCR, et al. Dietary docosahexaenoic acid (DHA) as lysophosphatidylcholine, but not as free acid, enriches brain DHA and improves memory in adult mice. Sci Rep 2017; 7: 11263.
[36] Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 2006; 60: 502–507.
[37] Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine & Pharmacotherapy 2002; 56: 365–379.
[38] Brenna JT, Salem N, Sinclair AJ, et al. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 85–91.
[39] Swanson D, Block R, Mousa SA. Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Adv Nutr 2012; 3: 1–7.
[40] Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci; 7. Epub ahead of print 2015. DOI: 10.3389/fnagi.2015.00052.
[41] Heshmati J, Morvaridzadeh M, Maroufizadeh S, et al. Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials. Pharmacological Research 2019; 149: 104462.
[42] Arshad Z, Rezapour-Firouzi S, Ebrahimifar M, et al. Association of Delta-6-Desaturase Expression with Aggressiveness of Cancer, Diabetes Mellitus, and Multiple Sclerosis: A Narrative Review. Asian Pac J Cancer Prev 2019; 20: 1005–1018.
[43] Opperman M. What health professionals should know about omega-3 fatty acid supplements. South African Journal of Clinical Nutrition 2013; 26: 6–11.
[44] Neubronner J, Schuchardt JP, Kressel G, et al. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. European Journal of Clinical Nutrition 2011; 65: 247–254.
[45] Beckermann B, Beneke M, Seitz I. [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers]. Arzneimittelforschung 1990; 40: 700–704.
[46] Peltomaa E, Johnson M, Taipale S. Marine Cryptophytes Are Great Sources of EPA and DHA. Marine Drugs 2017; 16: 3.
[47] Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. Journal of the American College of Cardiology 2009; 54: 585–594.
[48] De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364: 2439–2450.
[49] Kiczorowska B, Samolinska W, Grela ER, et al. Nutrient and Mineral Profile of Chosen Fresh and Smoked Fish. Nutrients; 11. Epub ahead of print 26 June 2019. DOI: 10.3390/nu11071448.
[50] Strobel C, Jahreis G, Kuhnt K. Survey of n- 3 and n-6 polyunsaturated fatty acids in fish and fish products. Lipids in Health and Disease 2012; 11: 144.
[51] Willemsen. Report on the seafood consumption data found in the European countries of the OT-SAFE project. W-03/42, Utrecht: Institute for Environmental Studies, http://www.ivm.vu.nl/en/Images/OT7DBA3C19-6B94-4471-BD772CB22C9544E7_tcm234-87248.pdf (2003).
[52] Hussey EK, Portelli S, Fossler MJ, et al. Relative Bioavailability of an Emulsion Formulation for Omega-3-Acid Ethyl Esters Compared to the Commercially Available Formulation: A Randomized, Parallel-Group, Single-Dose Study Followed by Repeat Dosing in Healthy Volunteers. Clin Pharmacol Drug Dev 2012; 1: 14–23.
[53] Dyerberg J, Madsen P, Møller JM, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids 2010; 83: 137–141.
[54] Garaiova I, Guschina IA, Plummer SF, et al. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. Nutr J 2007; 6: 4.
[55] Harris W. Omega-6 and omega-3 fatty acids: partners in prevention: Current Opinion in Clinical Nutrition and Metabolic Care 2010; 13: 125–129.
[56] O’Keefe EL, Harris WS, DiNicolantonio JJ, et al. Sea Change for Marine Omega-3s. Mayo Clinic Proceedings 2019; 94: 2524–2533.
[57] Del Gobbo LC, Imamura F, Aslibekyan S, et al. ?-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. JAMA Intern Med 2016; 176: 1155–1166.
[58] Ouchi S, Miyazaki T, Shimada K, et al. Decreased circulating dihomo-gamma-linolenic acid levels are associated with total mortality in patients with acute cardiovascular disease and acute decompensated heart failure. Lipids Health Dis 2017; 16: 150.
[59] Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006; 84: 5–17.
[60] Lewington S, Withlock G, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–1839.
[61] Boshuizen HC, Lanti M, Menotti A, et al. Effects of past and recent blood pressure and cholesterol level on coronary heart disease and stroke mortality, accounting for measurement error. Am J Epidemiol 2007; 165: 398–409.
[62] Houterman S, Verschuren WMM, Kromhout D. Smoking, blood pressure and serum cholesterol-effects on 20-year mortality. Epidemiology 2003; 14: 24–29.
[63] Bernstein AM, Ding EL, Willett WC, et al. A Meta-Analysis Shows That Docosahexaenoic Acid from Algal Oil Reduces Serum Triglycerides and Increases HDL-Cholesterol and LDL-Cholesterol in Persons without Coronary Heart Disease. J Nutr 2012; 142: 99–104.
[64] Marchioli R, Barzi F, Bomba E, et al. Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897–1903.
[65] Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation 2017; 135: e867–e884.
[66] Kris-Etherton Penny M., Harris William S., Appel Lawrence J. Omega-3 Fatty Acids and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23: 151–152.
[67] Reimers A, Ljung H. The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders. Ther Adv Psychopharmacol; 9. Epub ahead of print 24 June 2019. DOI: 10.1177/2045125319858901.
[68] Hibbeln JosephR, Gow RV. Omega-3 Fatty Acid and Nutrient Deficits in Adverse Neurodevelopment and Childhood Behaviors. Child Adolesc Psychiatr Clin N Am 2014; 23: 555–590.
[69] Escolano-Margarit MV, Ramos R, Beyer J, et al. Prenatal DHA status and neurological outcome in children at age 5.5 years are positively associated. J Nutr 2011; 141: 1216–1223.
[70] Montgomery P, Burton JR, Sewell RP, et al. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS One 2013; 8: e66697.
[71] Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014; 34: 496–505.
[72] Parletta N, Niyonsenga T, Duff J. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls. PLoS One 2016; 11: e0156432.
[73] Widenhorn-Müller K, Schwanda S, Scholz E, et al. Effect of supplementation with long-chain ?-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. Prostaglandins Leukot Essent Fatty Acids 2014; 91: 49–60.
[74] Checa-Ros A, Haro-García A, Seiquer I, et al. Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids. Minerva Pediatr 2019; 71: 313–325.
[75] Raine A, Fung ALC, Gao Y, et al. Omega-3 supplementation, child antisocial behavior, and psychopathic personality: a randomized, double-blind, placebo-controlled, stratified, parallel group trial. Eur Child Adolesc Psychiatry. Epub ahead of print 28 March 2020. DOI: 10.1007/s00787-020-01513-8.
[76] Raine A, Ang RP, Choy O, et al. Omega-3 (w3) and social skills interventions for reactive aggression and childhood externalizing behavior problems: a randomized, stratified, double-blind, placebo-controlled, factorial trial. Psychol Med 2019; 49: 335–344.
[77] Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. Br J Nutr 2003; 89: 483–489.
[78] Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromolecular Med 2008; 10: 219–235.
[79] Lin P-Y, Chiu C-C, Huang S-Y, et al. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry 2012; 73: 1245–1254.
[80] van Gelder BM, Tijhuis M, Kalmijn S, et al. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85: 1142–1147.
[81] Morris MC, Evans DA, Tangney CC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62: 1849–1853.
[82] Sakamoto T, Cansev M, Wurtman RJ. Oral Supplementation with Docosahexaenoic Acid and Uridine-5’-Monophosphate Increases Dendritic Spine Density in Adult Gerbil Hippocampus. Brain Res 2007; 1182: 50–59.
[83] Canhada S, Castro K, Perry IS, et al. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: A systematic review. Nutr Neurosci 2018; 21: 529–538.
[84] La Rosa F, Clerici M, Ratto D, et al. The Gut-Brain Axis in Alzheimer’s Disease and Omega-3. A Critical Overview of Clinical Trials. Nutrients; 10. Epub ahead of print 8 September 2018. DOI: 10.3390/nu10091267.
[85] Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402–1408.
[86] Hooper C, De Souto Barreto P, Coley N, et al. Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index. J Nutr Health Aging 2017; 21: 988–993.
[87] Lau LML de, Bornebroek M, Witteman JCM, et al. Dietary fatty acids and the risk of Parkinson disease: The Rotterdam Study. Neurology 2005; 64: 2040–2045.
[88] Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007; 86: 1486–1494.
[89] Okubo H, Miyake Y, Sasaki S, et al. Dietary patterns and risk of Parkinson’s disease: a case-control study in Japan. Eur J Neurol 2012; 19: 681–688.
[90] Taghizadeh M, Tamtaji OR, Dadgostar E, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int 2017; 108: 183–189.
[91] Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243–251.
[92] Jamilian H, Solhi H, Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob J Health Sci 2014; 6: 103–108.
[93] Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596–1598.
[94] Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, et al. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016; 73: 34–44.
[95] Berger GE, Proffitt T-M, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1867–1875.
[96] Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146–154.
[97] Lindqvist HM, Gjertsson I, Eneljung T, et al. Influence of Blue Mussel (Mytilus edulis) Intake on Disease Activity in Female Patients with Rheumatoid Arthritis: The MIRA Randomized Cross-Over Dietary Intervention. Nutrients; 10. Epub ahead of print 13 April 2018. DOI: 10.3390/nu10040481.
[98] Abdulrazaq M, Innes JK, Calder PC. Effect of ?-3 polyunsaturated fatty acids on arthritic pain: Asystematic review. Nutrition 2017; 39–40: 57–66.
[99] Dawczynski C, Hackermeier U, Viehweger M, et al. Incorporation of n-3 PUFA and ?-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. Lipids Health Dis 2011; 10: 130.
[100] Veselinovic M, Vasiljevic D, Vucic V, et al. Clinical Benefits of n-3 PUFA and ?-Linolenic Acid in Patients with Rheumatoid Arthritis. Nutrients 2017; 9: 325.
[101] Hurst S, Zainal Z, Caterson B, et al. Dietary fatty acids and arthritis. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 315–318.
[102] Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683–747.
[103] Kouchaki E, Afarini M, Abolhassani J, et al. High-dose ?-3 Fatty Acid Plus Vitamin D3 Supplementation Affects Clinical Symptoms and Metabolic Status of Patients with Multiple Sclerosis: A Randomized Controlled Clinical Trial. The Journal of Nutrition 2018; 148: 1380–1386.
[104] Nordvik I, Myhr KM, Nyland H, et al. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000; 102: 143–149.
[105] McCusker MM, Grant-Kels JM. Healing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids. Clin Dermatol 2010; 28: 440–451.
[106] Landi G. ORAL ADMINISTRATION OF BORAGO OIL IN ATOPIC DERMATITIS. 5.
[107] Jung J, Kwon H, Hong J, et al. Effect of Dietary Supplementation with Omega-3 Fatty Acid and Gamma-linolenic Acid on Acne Vulgaris: A Randomised, Double-blind, Controlled Trial. Acta Derm Venerol 2014; 94: 521–525.
[108] John S, Luben R, Shrestha SS, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol 2010; 22: 602–606.
[109] Cotogni P, Muzio G, Trombetta A, et al. Impact of the omega-3 to omega-6 polyunsaturated fatty acid ratio on cytokine release in human alveolar cells. JPEN J Parenter Enteral Nutr 2011; 35: 114–121.
[110] Tabak C, Smit HA, Heederik D, et al. Diet and chronic obstructive pulmonary disease: independent beneficial effects of fruits, whole grains, and alcohol (the MORGEN study). Clin Exp Allergy 2001; 31: 747–755.
[111] Stoodley I, Garg M, Scott H, et al. Higher Omega-3 Index Is Associated with Better Asthma Control and Lower Medication Dose: A Cross-Sectional Study. Nutrients 2020; 12: 74.
[112] Brigham EP, Woo H, McCormack M, et al. Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children. Am J Respir Crit Care Med 2019; 199: 1478–1486.
[113] Scoditti E, Massaro M, Garbarino S, et al. Role of Diet in Chronic Obstructive Pulmonary Disease Prevention and Treatment. Nutrients 2019; 11: 1357.
[114] Blachnio-Zabielska AU, Chacinska M, Vendelbo MH, et al. The Crucial Role of C18-Cer in Fat-Induced Skeletal Muscle Insulin Resistance. Cell Physiol Biochem 2016; 40: 1207–1220.
[115] Chacinska M, Zabielski P, Ksiazek M, et al. The Impact of OMEGA-3 Fatty Acids Supplementation on Insulin Resistance and Content of Adipocytokines and Biologically Active Lipids in Adipose Tissue of High-Fat Diet Fed Rats. Nutrients; 11. Epub ahead of print 12 April 2019. DOI: 10.3390/nu11040835.
[116] Albracht-Schulte K, Kalupahana NS, Ramalingam L, et al. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. The Journal of Nutritional Biochemistry 2018; 58: 1–16.
[117] Sampalis F, Bunea R, Pelland MF, et al. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev 2003; 8: 171–179.
[118] Sohrabi N, Kashanian M, Ghafoori SS, et al. Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: ‘a pilot trial’. Complement Ther Med 2013; 21: 141–146.
[119] Watanabe S, Sakurada M, Tsuji H, et al. Efficacy of g-linolenic Acid for Treatment of Premenstrual Syndrome, as Assessed by a Prospective Daily Rating System. J Oleo Sci 2005; 54: 8.
[120] Lucas M, Asselin G, Mérette C, et al. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2009; 16: 357–366.
[121] Lucas M, Asselin G, Mérette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009; 89: 641–651.
[122] Chiu Y-H, Karmon AE, Gaskins AJ, et al. Serum omega-3 fatty acids and treatment outcomes among women undergoing assisted reproduction. Hum Reprod 2018; 33: 156–165.
[123] Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31: 679–692.
[124] Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529–1539.
[125] Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96: 350–353.
[126] Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. Nutrition, Metabolism and Cardiovascular Diseases 2013; 23: 1066–1070.
[127] Nobili V, Carpino G, Alisi A, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One 2014; 9: e88005.
[128] Setty BNY, Betal SG, Miller RE, et al. Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia. Prostaglandins Leukot Essent Fatty Acids 2019; 146: 11–18.
[129] Daak AA, Ghebremeskel K, Hassan Z, et al. Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2013; 97: 37–44.
[130] Chong EW-T, Wong TY, Kreis AJ, et al. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007; 335: 755.
[131] van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294: 3101–3107.
[132] Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr 2011; 31: 321–351.
[133] SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Progress in Retinal and Eye Research 2005; 24: 87–138.
[134] van Leeuwen EM, Emri E, Merle BMJ, et al. A new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res 2018; 67: 56–86.
[135] Delyfer M-N, Buaud B, Korobelnik J-F, et al. Association of Macular Pigment Density with Plasma Omega-3 Fatty Acids: The PIMAVOSA Study. Invest Ophthalmol Vis Sci 2012; 53: 1204–1210.
[136] Guo S, DiPietro LA. Factors Affecting Wound Healing. J Dent Res 2010; 89: 219–229.
[137] Moor AN, Vachon DJ, Gould LJ. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Repair and Regeneration 2009; 17: 832–839.
[138] Elkhouli AM. The efficacy of host response modulation therapy (omega-3 plus low-dose aspirin) as an adjunctive treatment of chronic periodontitis (clinical and biochemical study). J Periodontal Res 2011; 46: 261–268.
[139] Terano T. Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis. World Rev Nutr Diet 2001; 88: 141–147.
[140] Tartibian B, Hajizadeh Maleki B, Kanaley J, et al. Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study. Nutrition & Metabolism 2011; 8: 71.
[141] Maroon JC, Bost JW. Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol 2006; 65: 326–331.
[142] Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. Vasc Health Risk Manag 2015; 11: 511–524.
[143] Toufektsian M-C, Salen P, Laporte F, et al. Dietary flavonoids increase plasma very long-chain (n-3) fatty acids in rats. J Nutr 2011; 141: 37–41.
[144] Rajarethnem H, Megur Ramakrishna Bhat K, Jc M, et al. Combined Supplementation of Choline and Docosahexaenoic Acid during Pregnancy Enhances Neurodevelopment of Fetal Hippocampus. Neurology Research International 2017; 2017: e8748706.
[145] Berbert AA, Kondo CRM, Almendra CL, et al. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition 2005; 21: 131–136.
[146] Mousavi Nasl-Khameneh A, Mirshafiey A, Naser Moghadasi A, et al. Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and ROR?t gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis. Neurol Res 2018; 40: 11–17.
[147] Cadario F, Savastio S, Rizzo A, et al. Favorable effects of omega-3 PUFAs on glucose control in an adolescent with type 1 diabetes using continuous glucose monitoring: a case report. CellR4 2020; 16.
[148] Jamilian M, Samimi M, Ebrahimi FA, et al. The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. J Clin Lipidol 2017; 11: 459–468.
